Cardiovascular

FDA allows marketing of first system to repair failed or problematic aortic endografts

The U.S. Food and Drug Administration is allowing marketing of the first system—a minimally invasive option—that can repair a failed or problematic aortic endograft. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares